Ultra-widefield imaging was found to have “moderate to substantial agreement” with ETDRS 7-field imaging to determine the severity of diabetic retinopathy.The cross-sectional study included 764 eyes. Both ETDRS 7-field and ultra-widefield images were e…
Author: Healio ophthalmology
Second Sight posts quarterly net loss
Second Sight Medical Products reported a net loss of $8.5 million, or $0.12 per share, in the third quarter of 2018 compared with a net loss of $6.7 million, or $0.12 per share, in 2017’s third quarter, according to a press release.Net sales totaled $2…
Zimura-Lucentis combination safe in wet AMD patients in phase 2a trial
Zimura, a complement factor C5 inhibitor, was found to be well tolerated in combination with Lucentis in a phase 2a clinical trial, Ophthotech announced in a press release.Sixty-four patients with wet age-related macular degeneration were enrolled in t…
Quarterly loss decreases for ProQR
ProQR Therapeutics reported a net loss of 6 million euros, or 0.18 euros per share, in the third quarter of 2018 compared with a net loss of 10.5 million euros, or 0.42 euros per share, in the previous year’s third quarter.Research and development cost…
Santen launches Verkazia in Europe to treat VKC in children
Santen U.K. Ltd. announced the launch of Verkazia eye drops in Europe for the treatment of severe vernal keratoconjunctivitis in adolescents and children at least 4 years old.Verkazia (0.1% cyclosporine), an immunomodulator that targets the underlying …
VIDEO: Web Vision Technologies seeks to create all-in-one vision testing device for NASA
CHICAGO At the American Academy of Ophthalmology meeting here, Bob Main, MS, CEO of Web Vision Technologies, discusses his company’s attempts to recruit visual testing companies to help it develop a multi-functional ophthalmic device, an all-in-one vis…
Dexycu receives permanent J-code
CMS has assigned a permanent reimbursement J-code for Dexycu through the Healthcare Common Procedure Coding System, EyePoint Pharmaceuticals announced in a press release.Dexycu (dexamethasone intraocular suspension) 9%, the first FDA-approved, single-d…
VIDEO: Preventing embezzlement critical to practice management
CHICAGO — At the American Academy of Ophthalmology meeting here, Cynthia Matossian, MD, FACS, discusses ways to prevent different forms of embezzlement in medical practices.
VIDEO: CorneaGen partners with Visiometrics
CHICAGO — At the Ophthalmology Innovation Summit at AAO, Monty Montoya, president and CEO of CorneaGen, discusses the company’s partnership with Visiometrics to increase use of the HD Analyzer and Tear Film Analyzer in the U.S.
VIDEO: ERG vision testing systems beneficial in clinical practice
CHICAGO — Steven Silverstein, MD, discusses pattern and flicker electrophysiology devices (Diopsys) for diagnosing, monitoring and treating patients with glaucoma and retinopathies at the American Academy of Ophthalmology meeting here.
VIDEO: Presbyopia-correcting eye drop formulation progresses in clinical trials
CHICAGO — At the Ophthalmology Innovation Summit at AAO, Elad Kedar, CEO of Orasis Pharmaceuticals, discusses the progress of the company’s eye drop CSF-1 for the treatment of presbyopia.
Puriton eye drops voluntarily recalled
Kadesh is voluntarily recalling all lots of Puriton Eye Relief Drops, 0.5 oz bottle, due to non-sterile production conditions at its manufacturing facility, the FDA announced in a press release.The over-the-counter homeopathic drops are marketed for te…
Minimally invasive corneal neurotization effective for neurotrophic keratopathy
CHICAGO — Minimally invasive corneal neurotization was successful in treating neurotrophic keratopathy, according to a speaker here.Older techniques for corneal neurotization, in which an intact sensory nerve is transferred to the back of the cornea to…
VIDEO: Sustained-release ranibizumab ‘exceeds expectations’ for wet AMD
CHICAGO — Carl D. Regillo, MD, gives an update on the phase 2 LADDER study, a four-arm trial of sustained-release ranibizumab (Genentech), at the American Academy of Ophthalmology meeting here.
Medicare hospital outpatient rate set for Argus II
The Medicare hospital outpatient rate for the Argus II retinal prosthesis system has been set at $152,500 by CMS, Second Sight Medical Products announced in a press release.Argus II is the only FDA- and CE mark-approved device for the treatment of reti…
Thyroid eye disease therapy shows promise
CHICAGO — Teprotumumab, an IGF-1 receptor antagonist antibody, demonstrated improvement of double vision in patients with thyroid eye disease, according to a study presented here.If approved by the FDA, teprotumumab (Horizon Pharma) would be the first …
VIDEO: Kala readies to launch Inveltys for cataract surgery
CHICAGO — At the Ophthalmology Innovation Summit at AAO, Mark Iwicki, chairman and CEO of Kala Pharmaceuticals, discusses the company’s plans to launch Inveltys (loteprednol etabonate ophthalmic suspension 1%), a twice-daily topical steroid, for the tr…
VIDEO: Oxurion introduces new clinical portfolio at OIS
CHICAGO At the Ophthalmology Innovation Summit at AAO, Patrik De Haes, MD, CEO of Oxurion, introduces the company’s new clinical portfolio with three separate molecules in clinical trials for the treatment of diabetic macular edema.
Repeated intravitreal sirolimus treatments improve vitreous haze
CHICAGO — The results of the integrated SAKURA program showed every-other-month dosing with intravitreal sirolimus improved ocular inflammation and vitreous haze in patients with non-infectious uveitis, according to a speaker here.Researchers evaluated…
Repeated intravitreal sirolimus treatments improve vitreous haze
CHICAGO — The results of the integrated SAKURA program showed every-other-month dosing with intravitreal sirolimus improved ocular inflammation and vitreous haze in patients with non-infectious uveitis, according to a speaker here.Researchers evaluated…